Abstract Background Rare diseases are life-threatening, serious, and chronic conditions that require complex care have a low prevalence. An estimated one in 15 people worldwide affected by rare diseases. This study aims to analyze the accessibility, reimbursement status, licensed Anatomical Therapeutic Chemical (ATC) codes of drugs European Medicines Agency (EMA) Turkey considers be “orphan” ph...